Journal of Clinical Endocrinology & Metabolism, Vol 71, 1356-1362, Copyright © 1990 by Endocrine Society

ARTICLES

Increased overnight growth hormone concentrations in diabetic compared with normal adolescents

JA Edge, DB Dunger, DR Matthews, JP Gilbert and CP Smith
Department of Paediatrics, John Radcliffe Hospital, Headington, United Kingdom.

To determine the extent to which spontaneous plasma GH concentrations are abnormal in adolescents with insulin-dependent diabetes mellitus we performed 12-h overnight plasma GH profiles in 21 diabetic adolescents (11 males and 10 females; aged 9.8-16.5 yr; median, 13.6 yr) and 34 healthy adolescent controls (17 males and 17 females; aged 9.1-20.9 yr; median, 13.1 yr). Data were analyzed using the pulse detection program Pulsar and time series analysis, and are presented with respect to age and puberty stage. Mean and maximum GH concentrations, sum of the peak amplitudes, and mean calculated baseline concentrations in the normal children were higher during puberty; highest levels were seen in girls at puberty stages 2-3, and in boys at stages 4-5. A similar pattern was observed in the diabetic adolescents, but all measures of pulse height and mean calculated baseline concentrations were significantly greater than those in the normal subjects (multivariate analysis, P less than 0.001). Pulse frequency did not change during puberty in the normal or diabetic subjects, and the dominant pulse periodicity in both groups was about 180 min. We conclude that the predominant change in GH release during puberty is in pulse amplitude, and that this is increased in diabetes, whereas pulse frequency remains constant in both normal and diabetic adolescents.

This article has been cited by other articles:

				E. Codner and H. F. Escobar-Morreale Hyperandrogenism and Polycystic Ovary Syndrome in Women with Type 1 Diabetes Mellitus J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1209 - 1216. [Abstract] [Full Text] [PDF]

				R Amin, T K Bahu, B Widmer, R N Dalton, and D B Dunger Longitudinal relation between limited joint mobility, height, insulin-like growth factor 1 levels, and risk of developing microalbuminuria: the Oxford Regional Prospective Study Arch. Dis. Child., October 1, 2005; 90(10): 1039 - 1044. [Abstract] [Full Text] [PDF]

				T. Saukkonen, R. Amin, R. M. Williams, C. Fox, K. C. Yuen, M. A. White, A. M. Umpleby, C. L. Acerini, and D. B. Dunger Dose-Dependent Effects of Recombinant Human Insulin-Like Growth Factor (IGF)-I/IGF Binding Protein-3 Complex on Overnight Growth Hormone Secretion and Insulin Sensitivity in Type 1 Diabetes J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4634 - 4641. [Abstract] [Full Text] [PDF]

				L. Ibanez, K. Ong, A. Ferrer, R. Amin, D. Dunger, and F. de Zegher Low-Dose Flutamide-Metformin Therapy Reverses Insulin Resistance and Reduces Fat Mass in Nonobese Adolescents with Ovarian Hyperandrogenism J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2600 - 2606. [Abstract] [Full Text] [PDF]

				R. Amin, C. Schultz, K. Ong, J. Frystyk, R. N. Dalton, L. Perry, H. Orskov, and D. B. Dunger Low IGF-I and Elevated Testosterone During Puberty in Subjects With Type 1 Diabetes Developing Microalbuminuria in Comparison to Normoalbuminuric Control Subjects: The Oxford Regional Prospective Study Diabetes Care, May 1, 2003; 26(5): 1456 - 1461. [Abstract] [Full Text] [PDF]

				J. Hamilton, E. Cummings, V. Zdravkovic, D. Finegood, and D. Daneman Metformin as an Adjunct Therapy in Adolescents With Type 1 Diabetes and Insulin Resistance: A randomized controlled trial Diabetes Care, January 1, 2003; 26(1): 138 - 143. [Abstract] [Full Text] [PDF]

				P. F. Catalina, F. Mallo, M. A. Andrade, R. V. García-Mayor, and C. Diéguez Growth Hormone (GH) Response to GH-Releasing Peptide-6 in Type 1 Diabetic Patients with Exaggerated GH-Releasing Hormone-Stimulated GH Secretion J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3663 - 3667. [Abstract] [Full Text]